Other
CN
EU
USA
Description: UPF 1069 (UPF-1069), an isoquinolinone derivative, is a novel, potent and selective inhibitor of poly-(ADP-ribose) polymerase 2 (PARP-2) with potential neurprotective and anti-ischemic effects in vivo. It inhibits PARP-2 with IC50s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively. It is able to induce apoptosis and reduce PAR formation both in recombinant enzyme preparations and in nuclear extracts from PARP-1-/- fibroblasts. UPF 1069 is more selective for PARP-2 than PARP-1 (IC50 = 8 μmol/L). It has been used to investigate the role of PARP-1 and PARP-2 in post-ischaemic brain damage.
References: Br J Pharmacol. 2009 Jul;157(5):854-62.
Product Catalog 2022
Guide to Product Handling
Synonym: UPF-1069, UPF 1069, UPF1069
Chemical Name: 5-(2-oxo-2-phenylethoxy)isoquinolin-1(2H)-one
InChi Key: JJWMRRNGWSITSQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H13NO3/c19-15(12-5-2-1-3-6-12)11-21-16-8-4-7-14-13(16)9-10-18-17(14)20/h1-10H,11H2,(H,18,20)
SMILES Code: O=C1NC=CC2=C1C=CC=C2OCC(C3=CC=CC=C3)=O
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: PF 1069 (Compound 55) is a PARP inhibitor, with IC50s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively. UPF 1069 (1 µM) reduces the residual PARP activity by approximately 80% of PARP-1-deficient fibroblasts, but only slightly inhibits the enzymic activity in wild-type fibroblasts. UPF 1069 (0.1-1 µM) markedly enhances CA1 hippocampal damage. UPF 1069 (10 µM) also exacerbates oxygen-glucose deprivation (OGD) damage in organotypic hippocampal slices. However, UPF 1069 alleviates the damage cuased by OGD in mixed cortical cell cultures, shows a potent neuroprotective activity both at a concentration (1 µM) selectively acting on PARP-2 and at a concentration (10 µM) inhibiting both PARP-1 and PARP-2 activities.
Kinase Assay: PARP activity is evaluated by utilizing commercially available recombinant bovine PARP-1 and mouse PARP-2. Briefly, the enzymatic reaction is carried out in 100 µL of 50 mM Tris-HCl (pH 8.0) containing 5 mM MgCl2, 2 mM dithiothreitol, 10 µg sonicated calf thymus DNA, 0.2 µCi [adenine-2,8-3H]NAD and recombinant enzyme PARP-1 or PARP-2 (0.03 U per sample). Different concentrations of the putative inhibitors are added, and the mixture is incubated for 1 h at 37°C. The reaction is terminated by adding 1 mL of 10% trichloroacetic acid (w/v) and centrifuged. Pellets are then washed twice with 1 mL of H2O and resuspended in 1 mL of 0.1 M NaOH. The radioactivity incorporated from [adenine-2,8-3H]NAD into proteins is evaluated by liquid scintillation spectrometry.
Br J Pharmacol. 2009 Jul;157(5):854-62.
Purity ≥98%